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Objective: Vein wall endothelial turnover after stasis deep vein thrombosis (DVT) has not been well characterized. The
purpose of this study was to quantify re-endothelialization after DVT and determine if low-molecular-weight heparin
(LMWH) therapy affects this process.
Methods: Stasis DVT was generated in the rat by inferior vena cava ligation, with harvest at 1, 4, and 14 days.
Immunohistologic quantification of vascular smooth muscle cells and luminal endothelialization was estimated by
positive staining for -smooth muscle actin and von Willebrand factor, respectively. In separate experiments, rats were
treated either before or after DVT with subcutaneous LMWH (3 mg/kg daily) until harvesting at 4 and 14 days. The
inferior vena cava was processed for histologic analysis or was processed for organ culture after the thrombus was gently
removed. The vein wall was stimulated in vitro with interleukin-1 (1 ng/mL), and the supernatant was processed at 48
hours for nitric oxide. Cells were processed by real-time polymerase chain reaction for endothelial nitric oxide synthase,
inducible nitric oxide synthase, cyclooxygenase-1 and -2, and thrombomodulin at 4 and 14 days, and collagen I and III
at 14 days. Comparisons were done with analysis of variance or t test. A P < .05 was significant.
Results: Thrombus size peaked at 4 days, whereas luminal re-endothelialization increased over time (1 day, 11%  2%;
4 days, 23%  4%; 14 days, 64%  7% () von Willebrand factor staining; P < .01, n  3 to 4, compared with non-DVT
control). Similarly, vascular smoothmuscle cell staining was lowest at day 1 and gradually returned to baseline by 14 days.
Both before and after DVT, LMWH significantly increased luminal re-endothelialization, without a difference in
thrombus size at 4 days, but no significant difference was noted at 14 days despite smaller thrombi with LMWH
treatment. Pretreatment with LMWH was associated with increased vascular smooth muscle cell area and recovery of
certain inducible endothelial specific genes. No significant difference in nitric oxide levels in the supernatant was found
at 4 days. At 14 days, type III collagen was significantly elevated with LMWH treatment.
Conclusions: Venous re-endothelialization occurs progressively as the DVT resolves and can be accelerated with LMWH
treatment, although this effect appears limited to the early time frame. These findings may have clinical relevance for
LMWH timing and treatment compared with mechanical forms of therapy. (J Vasc Surg 2008;47:616-24.)
Clinical Relevance: How the vein wall endothelium responds after deep vein thrombosis (DVT) has not been well
documented owing to limited human specimens. This report shows that low-molecular-weight heparin accelerates or
protects the endothelium and preserves medial smooth muscle cell integrity after DVT, but that this effect is limited to
a relatively early time period. Although most DVT prophylaxis is pharmacologic (a heparin agent), use of nonpharma-
cologic measures is also common. The use of heparin prophylaxis, compared with after DVT treatment, and the
acceleration of post-DVT re-endothelialization require clinical correlation.The pathobiology of deep vein thrombosis (DVT)
resolution is complex, inflammatory in nature, and results
in vein wall injury. The mechanical and biochemical effect
of the thrombus, in juxtaposition to the vein wall directs
this process. Clinically, post-DVT sequelae include post-
thrombotic syndrome, recurrent DVT, and pulmonary em-
bolism (PE). At the organ level, DVT resolution is accom-
panied by valvular dysfunction and stiff vein walls that
manifest as venous hypertension with pain, swelling, and
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616sometimes recalcitrant ulceration.1,2 Heparin anticoagula-
tion is the standard of care for DVT treatment and is proven
to significantly reduce the risk of PE, as well as recurrent
DVT.3,4 A recent report suggests that rapid anticoagula-
tion with low-molecular-weight heparin (LMWH) may
decrease the incidence of post-thrombotic syndrome, but
the mechanisms are not clear, and patient heterogeneity in
outcomes exists.5
The mechanical and inflammatory insult caused by an
acute DVT is now fairly well characterized in animal mod-
els.6 Common amongst all models is the early influx
of polymorphonuclear (PMN) neutrophils, followed by
monocytes, thrombus neovascularization, and fibrosis.
Both the lysing thrombus as well as the mechanical effect of
the thrombotic occlusion likely causes vein wall endothelial
damage.
Arterial injury models suggest that more rapid and
complete endothelialization (return of endothelium after
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hyperplasia, a form of fibrotic injury. For example, exoge-
nous administration of granulocyte-monocyte colony stim-
ulating factor and 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase agents have been shown to accel-
erate re-endothelialization and reduce vessel injury.7,8 Mo-
darai et al9 have shown that circulating endothelial progen-
itor cells increase after experimental DVT and localize to
the resolving thrombus.9 The vein wall is also characterized
by different endothelial markers than arterial endothelium,
with less tissue plasminogen activator, similar thrombo-
modulin (TM), but more von Willebrand factor (vWF)
expression.10,11 To our knowledge, no experimental mod-
els of DVT have yet characterized the vein luminal endo-
thelial response over time.
The contribution of the basement membrane and vas-
cular smooth muscle cells (VSMCs) in directing and sup-
porting endothelialization after injury has been described in
the arterial system,10,12,13 but less so in the venous system.
Vascular injury promotes VSMC proliferation, migration,
and promotes a cellular synthetic state.11,14,15 Exposure of
the basement membrane proteins to circulating blood after
injury also stimulates thrombus formation. For example,
factor XI is an integral component of the subendothelial
matrix and is a proximal enzyme for the intrinsic pathway of
thrombosis. Thus, another pathologic aspect of endothelial
loss in the venous system may be potentiation of thrombo-
sis. Lastly, the vein wall, unlike the arterial system, is subject
to larger distending forces but lower pressures, and these
biomechanical factors may also affect the injury response.
The goal of the current study is to delineate the endo-
thelial response of the vein wall to stasis thrombosis, both in
vivo and in vitro, and to evaluate the effect of LMWH
treatment before and after thrombosis. We hypothesized
that vein wall re-endothelialization would be independent
of DVT size and hastened by treatment with LMWH.
METHODS
Animal model. Male Sprague-Dawley rats (250-350 g)
were used for all studies, and all protocols were approved by
the University of Michigan Animal Care Committee. For
all surgical procedures, the rats underwent general anesthe-
sia with isoflurane and oxygen, with full physiologic mon-
itoring. Thrombosis was induced by inferior vena cava
(IVC) ligation to produce a stasis thrombus as de-
scribed.16-18 Briefly, a laparotomy with ligation of the IVC
below the renal veins and all visible side branches was
performed. At 1, 4, and 14 days, the thrombosed IVC was
carefully dissected and removed for histologic analysis, and
separate tissue studies were done after thrombus vein wall
separation at 4 and 14 days. The control for this group was
a sham operation with no IVC ligation, harvested at 4 days.
For treatment groups, the thrombosed control was
IVC ligation, with daily saline injection subcutaneously
(SubQ), and harvest at 4 and 14 days. The prethrombosis
group received the LMWH Lovenox (AstraZeneca, Chi-
cago, Ill), 3 mg/kg SubQ 1 hour before IVC ligation and
every day postoperatively, with harvest on day 4 or 14 days.The post-thrombosis LMWH treatment group received
LMWH, 3 mg/kg SubQ on days 2 and thereafter postop-
eratively, with harvest on day 4 or 14. The dosages were
based on prior experimental studies in rats.19,20 This strat-
egy allowed comparison of the timing of the LMWH, and
we acknowledge that the prethrombosis dosing was not at
prophylactic levels.
Deep vein thrombosis resolution. A reliable measure
of thrombus resolution is its weight-to-length measure,
harvested fresh.17,19,21
Immunohistochemical staining. Immunohistoche-
mical staining was performed on the paraffin-embedded
tissue sections (10 m) as described.16,22 The midsection
of each thrombosed vein was used for consistency of anal-
ysis. No significant differences were found comparing the
proximal or distal segments of vein (not shown), but an
intact full vein wall for analysis was most consistently
present in the midsection. The antibodies used were anti-
vWF (Rabbit Anti-Human, Chemicon, Temecula, Calif)
anti–-smooth muscle actin (Mouse Monoclonal SMA,
Abcam, Cambridge, Mass), anti-ED-1 (1:100; Mouse Anti-
Rat CD68, Serotec, Raleigh, NC) and anti-PMN (1:500,
Accurate Chemical, Westbury, CT). A species-specific ABC
peroxidase kit for rabbit, goat, or mouse (Vector Labora-
tories Inc, Burlingame, Calif) was used according to the
manufacturer’s instructions for the secondary antibody and
subsequent steps.
Color development was performed with diaminoben-
zidine (DAB, Vector Laboratories). The slides were coun-
terstained hematoxylin only with the ED-1 and PMN
stains. To quantify monocyte (ED-1) and PMN cellular-
positive staining, direct blinded counting of cells in five
high-power fields (1000 original magnification) radially
around the IVC wall was performed.
Von Willebrand factor and -smooth muscle actin
analysis. Permanent histologic sections that underwent
the described immunohistochemical staining with antibod-
ies vWF and -SMA application underwent standard color
development timing to allow consistency in color develop-
ment as described.22,23 This limits variability in stain qual-
ity, and no hematoxylin counterstain was applied. These
stained sections were captured using the Zeiss Axio Imager
M1 microscope, Axio Cam, and Axiovision 4.6 software
(Berlin, Germany) under 200 objective. Images were
acquired using a mosaic technique to facilitate analysis of a
complete image of IVC wall and clot (when present).
Positive vWF-stained cell layer measurements along the
lumen of the vein wall were made using the curve spline
tool. This allowed direct measure of the total circumference
and correction for shape irregularities. Area measurements
using the outline tool were done for -SMA–stained IVC
wall and corrected to IVC size using the wall circumference
measurement, yielding cross-sectional area.
In vitro vein wall culture and analysis. The IVCs
were harvested at 4 and 14 days in the sham (4 days only),
ligated control, and LMWH treatment groups, and placed
in cold Dulbecco phosphate buffered saline with 2 peni-
cillin/streptomycin/glutamine (Gibco, Invitrogen, Carls-
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The IVCs were cut lengthwise, weighed, and each half was
cut into 3 to 4 pieces and then placed inDulbeccoModified
Eagle Medium (Gibco) with interleukin 1- (1 ng/mL,
Mouse Recombinant, Sigma Aldrich, St. Louis, Mo) in a
12-well plate.24-26 The tissue culture was incubated at
37°C in 5% carbon dioxide for 48 hours. The wet weight of
each lengthwise IVC tissue sample was measured and then
frozen at 70°C for polymerase chain reaction (PCR)
processing. Culture media was spun at 5000g and the
supernatant removed and frozen at 70° C.
Quantitative real time polymerase chain reaction.
Expression of -actin, inducible nitric oxide synthase
(iNOS), endothelial nitric oxide synthase (eNOS), throm-
bomodulin (TM), cyclooxygenase (COX) -1 and -2, and
procollagen I, III, was determined from the harvested in
vitro cell tissue, as follows:
Messenger RNA (mRNA) was isolated by treatment of
vein wall segments with TRIzol reagent and reverse tran-
scribed by incubating with Oligo-(dT) primer andM-MLV
Reverse Transcriptase (Life Technologies, Carlsbad, Calif)
at 94°C for 3 minutes, followed by 40°C for 70 minutes.
The resultant complimentary DNA was amplified by Taq
Polymerase (Promega, Madison, Wisc) in the SmartCycler
quantitative PCR system (Cepheid, Sunnyvale, Calif).
Primers sequences were derived using Primer Premier
Software (Premier Biosoft International, Palo Alto, Calif)
based on primary mRNA sequences from GenBank (http://
www.ncbi.nlm.nih.gov/Genbank/). Relative mRNA expres-
sion was calculated by the formula 2 (Ct target gene Ct
reference gene) and cycle lengths used were within the expo-
nential phase of the PCR.27 The following sequences were
used:
iNOS Sense–CCC GAA ACG CTA CAC T, Anti-
Fig 1. A, Thrombus size peaks at day 4 after ligatio
weight-to-length measure only (n  5-8). *P  .05. B
factor (vWF) over time after stasis thrombosis or sham co
muscle actin (-SMA) staining in medial vein wall, correc
(n  4).*P  .05. DVT, Deep vein thrombosis; VSMC,
error.Sense–CGG CTG GAC TTC TCA C.eNOS Sense–GTT TGT CTG CGG CGA TGT, Anti-
Sense–GTG CGT ATG CGG CTT GTC.
TM Sense–ACC AGT CGC CTC CAC TTT, Anti-
Sense–TTC TCG CAC GGC TTC TC.
COX-1 Sense–GAA CCA AAGGGA AGA AGC, Anti-
Sense–GCA AAG AAA GCA AAC AAG A.
COX-2 Sense–CAG GTC ATC GGT GGA G, Anti-
Sense–AGG TGC TCA GGG ACG.
Col I Sense–AGG GAC ACA GAG GTT TCA GTG,
Anti-Sense–ACC ATT GGC ACC TTT AGC ACG.
Col III Sense–CCA CCC TGA ACT CAA GAG CGG,
Anti-Sense–CCA TCC TCT AGA ACT GTG TAA GTG.
Nitric oxide assay. The vein wall tissue culture super-
natant was harvested and stored as described. Nitric oxide
was measured in the culture media using the Nitrate/
Nitrite Colorimetric Assay Kit (Cayman, Ann Arbor, Mich)
according to manufacturer instructions.
Statistical analysis. All data are represented as
mean  SE. Unpaired Student t test and one-way analysis
of variance were used as appropriate for comparison be-
tween the groups at their individual time points and appro-
priate controls. Calculations were done with SigmaStat
software (SPSS, Chicago, Ill) A P  .05 was assigned
significance.
RESULTS
Deep vein thrombosis resolution is accompanied by
loss of endothelium and vascular smooth muscle cell
staining. The thrombosed IVC size was greatest at 4 days,
and trended down by 14 days (n  5 to 8; Fig 1, A). Note
the shams were purely the IVC weight. Post-DVT re-
endothelialization, as measured by the percentage of lumi-
nal vWF-positive staining, showed a steady increase from 1
am operation group is the inferior vena cava (IVC)
centage of luminal staining positive for von Willebrand
(n 3-4).*P .05.C,Cross-sectional area of -smooth
r circumference, after stasis thrombosis or sham control
lar smooth muscle cells. Error bars signify the standardn. Sh
, Per
ntrol
ted fo
vascuto 14 days, with only 17% luminal staining at day 1, but
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cantly less than the sham (n  3 to 4; P  .05; Fig 1, B).
Similarly, -SMA–positive medial vessel staining, reflective
of VSMC area, showed a significant decrease on days 1 and
4 by 64%, and 60% (n  4, P  .05), respectively, with
return toward sham at 14 days (Fig 1, C).
In vivo vein wall response to LMWH treatment
before and after thrombosis. Given the baseline kinetics
of the poststasis DVT vein wall re-endothelialization, the
greatest change seemed to occur between 4 and 14 days.
We chose these two time points to further analyze. These
two time points also represent an acute-to-chronic phase of
vein wall remodeling after DVT.6,16,17
At 4 days, treatment with LMWH either before or after
thrombosis did not significantly affect overall thrombus
size compared with the nontreated thrombosed controls
(Fig 2, A). By 14 days, the thrombus size was significantly
reduced with LMWH treatment before or after thrombosis
compared with thrombosed control by 23% to 37% (n  4
Fig 2. A, Thrombus size with vehicle treatment prethrombosis
and post-thrombosis low molecular weight heparin (LMWH)
treatment. No significant difference was observed. B, Thrombus
size with vehicle, and prethrombosis and post-thrombosis LMWH
treatment. Treatment with LMWH before and after thrombosis
was associated with smaller thrombi (n  6-8). *P  .05. IVC,
Inferior vena cava. Error bars signify the standard error.treatments; n  6 controls, P  .05; Fig 2, B).Monocyte influx, estimated by ED-1 staining, was not
significantly altered by LMWH treatments compared with
thrombosed control at either 4 or 14 days (4 day throm-
bosed control. 20 7; pre-LMWH, 15 4; post-LMWH,
27  9; cells/5 hpf, n  4 treatment; n  7 controls; P 	
.05). There was a fourfold reduction in overall vein wall
monocytes at 14 days compared with the 4-day time point
(thrombosed control, 5  2; pre, 5  1; post, 6  2,
cells/5 hpf). Sham controls showed fewmonocytes present
in the vein wall with no thrombus present (1.4 1 cells/5
hpf; n 4). No significant difference was observed in PMN
vein wall influx at 4 days and was not analyzed at 14 days
given the low vein wall numbers at this time point28 (data
not shown).
At 4 days, the prethrombosis and post-thrombosis
LMWH treatment groups had significantly greater luminal
vWF-positive staining compared with thrombosed controls
(n  4, treatments; n  7, controls; P  .05; Fig 3, A-D).
At 14 days, compared with ligated controls, there was no
significant difference in luminal vWF-positive staining, and
all groups ranged between 65% and 70% positive staining of
the vein lumen (n  6).
Similarly, at 4 days, -SMA medial vein wall–positive
staining was reduced in all groups (compared with sham) in
the thrombosed control, and post-DVT LMWH treat-
ment, but not with the pre-LMWH treatment (n  5
treatment; n  8 controls; Fig 4, A-D). No significant
differences in the -SMA-positive staining area were found
at 14 days between groups (n  5 to 6).
In vitro vein wall response of prophylactic and
low-molecular-weight heparin treatment after deep
vein thrombosis. To determine the induction of endothe-
lial gene expression from the thrombus-conditioned vein
wall tissue culture, we evaluated one nonendothelial related
gene and several endothelial related genes.10 The gene
induction was driven in vitro by a standard proinflamma-
tory agent, IL-1.24,25
Evaluating a nonendothelial derived gene, iNOS, we
found no significant differences in expression at 4 days and
overall low gene expression consistent with the sham non-
thrombosed control. In contrast, at 14 days, only the
thrombosed control showed significantly increased iNOS
expression (n 5 to 6, P .05; Fig 5,A), whereas LMWH
treatment after thrombosis was associated with significantly
lower gene expression compared with sham control.
Evaluating endothelial specific genes at 4 days, eNOS
and TM showed a similar expression pattern. The throm-
bosed group and post-thrombosis LMWH groups had
significantly reduced eNOS gene expression compared with
the sham control (n  4, treatment; n  6 control; P 
.05). However, prethrombosis LMWH treatment was as-
sociated with a nonsignificant reduction in eNOS expres-
sion compared with the sham control (P  .12; Fig 5, B).
At 14 days, overall eNOS expression was reduced approxi-
mately sixfold compared with the 4-day time point, and no
differences between the thrombosed control, prethrombo-
sis, and post-thrombosis treatment LMWH groups were
found.
arrow
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to the eNOS expression pattern (Fig 5, C). The prethrom-
bosis LMWH treatment group had a nonsignificant reduc-
tion in TM expression compared with the sham control,
whereas the thrombosed group and the post-thrombosis
LMWH group showed significantly reduced TM gene ex-
pression (n  6 treatments; n  8 controls; P  .05). In
contrast to the eNOS pattern, the sham, prethrombosis,
and post-thrombosis treatment LMWH groups were not
significantly different at day 14, and overall low gene ex-
pression was found (not shown). In contrast, the throm-
bosed control had a 10-fold increased TM gene expression
(n  4 treatment; n  7 controls; P  .05).
Evaluation of COX-1 and COX-2 gene expression
showed no significant differences among sham, throm-
bosed, and the prethrombosis and post-thrombosis
LMWH groups at 4 or 14 days (data not shown).
As the vessel wall remodels in the chronic phase, colla-
gen turnover occurs.29 Collagen production is dependent
on the synthetic activities of VSMC. To reflect this process,
we evaluated collagen gene expression at the 14-day time
point. No significant difference in collagen I gene expres-
sion was found when comparing all groups. However,
collagen III expression was significantly elevated in the
prethrombosis and post-thrombosis treatment LMWH
Fig 3. A, Graphic representation of vehicle (none), an
heparin (LMWH) effect on percentage of positive v
A significantly greater luminal area was positive for vW
standard error. DVT, Deep vein thrombosis. B, Examp
endothelial layer. Brown stain indicates the endothelium
thrombosed inferior vena cava. A large thrombus is see
staining (arrow), at 400 original magnification. W, V
thrombus (T) but more luminal positive vWF staining (group compared with the sham (n  5 treatment; n  8control; P  .05). The thrombosed group was not signifi-
cantly different then the sham control group (Fig 5, D).
Because eNOS gene expression was different between
treatments at 4 days, NO was evaluated. We found that
compared with the shams, all three groups had similar levels
of nitrite/nitrate, with no significant differences among the
groups. All were lower than the nonthrombosed sham
control group by approximately 40% (n 5 to 6, P .05).
DISCUSSION
These experiments suggest that stasis DVT causes an
initial loss of endothelium that recovers towards sham
controls within 14 days and affects the underlying VSMC
integrity. Further, prethrombosis and, to a lesser extent,
post-thrombosis treatment with LMWH may accelerate
re-endothelialization or protect the venous endothelium
and preserve the medial VSMC integrity. This effect was
most striking at 4 days after thrombosis and less so at 14
days, despite a smaller thrombus in the LMWH treatment
groups. This suggests some disconnect between the bene-
ficial effect of heparin and thrombolysis; that is, smaller
thrombi do not necessarily portend greater endothelial
recovery.
Heparin agents have pluripotent effects beyond antico-
agulation. For example, LMWH, by way of sialyl Lewis
thrombosis and post-thrombosis low-molecular-weight
illebrand factor (vWF) luminal staining at 4 days.
h LMWH treatment (n  4-7). Error bars signify the
sham inferior vena cava stained for vWF to denote the
ows) at 400 original magnification. C, Vehicle (none)
h luminal staining and a small amount of luminal vWF
all. D, Prethrombosis LMWH treatment. Note large
s) at 400 original magnification. W, Vein wall.d pre
on W
F wit
le of
(arr
n wit
ein wantigen, may block selectin interactions.30 Low-molecular-
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involving inhibition of lymphocyte and chemokine re-
sponses that are likely also at work in this system.30-32
A recently published study using a temporary clip model of
experimental thrombosis suggested that LMWH had a
greater anti-inflammatory effect than urokinase plasmino-
gen activator, as measured by vein wall tumor necrosis
factor- expression.33
Arterial injury models suggest that the presence of
endothelium plays a major role in vessel wall healing and
recovery; for example, in mice with impaired endotheliali-
zation after mechanical injury, increased neointimal hyper-
plasia is observed.7,8 We cannot answer whether the
prethrombosis LMWH protected the vein wall from endo-
thelial loss, increased local endothelial regeneration, or
increased endothelial progenitor cells to migrate to the
injured area.We did not find significant positive staining for
CD 133 or vascular endothelial growth factor receptor-2,
two markers of endothelial progenitor cells, at 1, 4, or 14
day time points in preliminary studies, suggesting local
regeneration or endothelial protection may play more of a
role than circulating progenitor cells.
A report in a rabbit jugular thrombosis model sug-
gested prophylactic treatment with unfractionated heparin
was protective for endothelial cells.34 A report by Modarai
et al9 suggests progenitor cells occupy the resolving throm-
Fig 4. A, Graphic representation of vehicle (none), an
heparin (LMWH) treatment on vein wall -smoothmusc
vein thrombosis; VSMC, vascular smooth muscle cell. B,
-SMA staining (arrows) at400 original magnification
thin brown -SMA area, at 4 days (arrows) at 4
D, Prethrombosis LMWH treatment. Not larger and m
tion. T, Thrombus; W, vein wall.bus, but it was not apparent whether these cells werepresent at the vein wall interface or whether they contribute
to endothelial recovery. Lastly, the endothelial protective
effect of LMWHwas probably not mediated bymonocytes,
because no differences were found in absolute numbers at
either 4 or 14 days by LMWH treatment within the vein
wall.
We analyzed the vein wall segments in vitro to deter-
mine the IL-1–inducible endothelial response genes that
are less easily defined with whole in vivo vein segment
analysis because less thrombus and peri-IVC tissue is
present with an in vitro tissue culture system. Specifically,
we hoped to be able to define the functional state of the
endothelium (tissue culture) to complement the immuno-
histologic findings. These strategies produce somewhat
different but overall consistent results.
First, prethrombosis LMWH treatment for experimen-
tal stasis thrombosis was associated with the greatest endo-
thelial recovery. This notion is supported by the signifi-
cantly increased luminal vWF-positive staining, the greater
-SMA area, as well as the nonsignificant decrease in spe-
cific endothelial homeostatic genes, eNOS and TM.
Second, post-thrombosis treatment with LMWH was
associated with greater luminal vWF staining but was not
associated with preserved eNOS or TM gene expression
compared with nonthrombosed IVC tissue culture.
Third, in vitro tissue culture analysis suggested dimin-
thrombosis and post-thrombosis low-molecular-weight
in (-SMA) area staining at 4 days (n 5-8).DVT,Deep
ple of sham control vein, showing brown medial area of
ein wall. C, Vehicle (none) treatment example showing
original magnification. T, Thrombus; W, vein wall.
iffuse -SMA area (arrows) at 400 original magnifica-d pre
le act
Exam
.W, V
00
ore dished endothelial gene expression related to the stasis
(n 
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damage is both mechanical with the stretch, but proba-
bly more so from the persistent thrombus–vein wall
interface. Thrombus leukocytes release proteinases, as
well as proinflammatory factors that may alter the base-
ment membrane. Recent data suggest the mechanisms of
thrombogenesis (stasis vs nonstasis) and the thrombus
itself primarily drives the injury.35 The local environment
of the exposed basement membrane components are also
important; namely, a high fibronectin/fibrin concentra-
tion produces a less hospitable environment for endothe-
lium.13 The endothelial protective effects were not as
striking at 14 days. Thus, persistence of thrombus, which
occurs in this stasis model, may negate the early benefi-
cial effect of LMWH.36
Preservation of the endothelium paralleled preservation
of the VSMC layer (-SMA area) and was observed with
prethrombosis, and to a lesser extent, post-thrombosis
LMWH treatment at 4 days. The -SMA antigen is also a
marker for VSMC contractible phenotype, which is the
physiological vasculae state.15 After injury, a synthetic phe-
notype predominates with loss of -SMA expression and is
Fig 5. Interleukin 1 (IL-1; 1 ng/mL) 48-hour stim
tissue was at 4 days or 14 days before harvest. A, Inducib
greater expression in the vehicle (none) thrombosed inf
post-thrombosis low-molecular-weight heparin (LMWH
synthase (eNOS) 4-day gene expression shows significan
treatment compared with sham (n  4-6). *P  .05
significantly reduced expression with vehicle and post-t
*P  .05. D, Collagen III expression at 14 days show
post-thrombosis LMWH treatment compared with shamresponsible for the fibrotic response and hyperplasia thatcan result. Although no difference in VSMC area was
observed at 14 days by immunohistology, IL-1–induced
type III collagen gene expression was significantly increased
with prethrombosis and, to a lesser extent post-thrombosis
LMWH treatment at 14 days. It is unlikely that a true
increase in collagen occurs in vivo, and indeed, prior work
has suggested less fibrosis with LMWH,20 as well as less
collagenolysis.35The fact that prethrombosis andpost-throm-
bosis LMWH treatment was associated with increased col-
lagen III gene expression also implies this may be part of
the normal healing response after DVT. Not surprisingly,
sham vein wall had a very low inducible type collagen III
gene expression and suggests the thrombus primes the vein
wall response.
The associated homeostatic gene product of eNOS is
NO, an essential mediator for vasodilation and antithrom-
botic properties of the vein wall.37,38 Of interest was that
supernatant NO levels were all reduced in vein tissue ex-
posed to thrombus. Although LMWH preserves eNOS
expression at 4 days, it was still reduced compared with
sham IVC tissue, and the diminished levels likely reflect this
fact. Similarly, TM confers an anticoagulant state to the
ed post-thrombosis vein wall tissue culture. Harvested
ic oxide synthase (iNOS) 14-day gene expression shows
vena cava (IVC) and significantly lesser expression with
atment (n  5). *P  .05. B, Endothelial nitric oxide
duced expression with vehicle and thrombosis LMWH
Thrombomodulin (TM) 4-day gene expression shows
bosis LMWH treatment compared with sham (n  6)
nificantly increased expression with prethrombosis and
4-5). *P  .05.ulat
le nitr
erior
) tre
tly re
. C,
hrom
s sigendothelium, in part, through its protein C interac-
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 3 Moaveni et al 623tion.39,40 The increased TM expression at the 14-day time
point may reflect a lag in re-endothelialization that occurs
in the setting of no LMWH treatment. Of interest was that
the major genes associated with prostaglandin production,
COX-1 and COX-2, were not induced differentially after
DVT. Cyclooxygenase inducibility by IL-1 has been doc-
umented but may drive cellular differentiation in vitro as
well as prostaglandin synthesis.26 Alternatively, endothelial
cells early after injury may not rely on the COX pathway
until a later chronic time point for prostaglandin produc-
tion. For example, chronic inhibition of COX-2 affects late
but not early arterial remodeling.41,42
CONCLUSION
The clinical translation of this experimental study is that
prethrombosis and, to a lesser extent, post-thrombosis
LMWH treatment may enhance early re-endothelialization
or protect the vein wall from endothelial loss. This may
explain why recurrent thrombosis is less likely with this
agent, in addition to its direct anticoagulation effect, and
has been suggested by others as well.35 A recent retrospec-
tive study also suggested that rapid, timely DVT treatment
may positively affect development of post-thrombotic syn-
drome.42 These data also beget the clinical question of
whether patients who develop a DVT who are receiving
prophylactic LMWH may have less long-term risk of post-
thrombotic syndrome than those receiving purely mechan-
ical prophylaxis.
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